Nanomedicine

简称 NANOMEDICINE-UK ·ENGLAND ·出版周期 Monthly ·年均收录 186 篇

3.9

最新影响因子

7.30%

自引率

约25%

投稿难度

平均6.0个月

审稿周期

期刊简介

Nanomedicine是一本国际学术期刊，ISSN号为1743-5889，由Future Medicine Ltd出版，出版地为英国，出版周期为月刊。该期刊的影响因子根据年份有所不同，最新数据需查阅官方来源，属于SCI收录期刊，中科院分区情况需参考最新分区表。Nanomedicine是一本开放获取（OA）期刊，专注于纳米技术在医学领域的应用研究，涵盖药物递送、诊断、治疗和生物材料等方向。其发文特点包括高水平的原创研究和综述文章，强调纳米医学的转化潜力和临床前景。期刊质量较高，但作为OA期刊，需注意版面费用和潜在的低质量投稿风险。总体而言，Nanomedicine是纳米医学领域的重要刊物，适合从事相关研究的学者投稿和阅读。

影响因子趋势

近期发表

Recent advances in the application of electrospun nanofibrous scaffolds in bone regeneration 2026-09-12

A novel rosiglitazone-phosphatidylserine composite nanoparticle mediated targeted drug delivery to macrophages for treatment of ulcerative colitis 2026-09-11

CRISPR-Cas9‑based lipid nanocarriers for advanced therapy of urinary bladder cancer 2026-09-10

Mucus-penetrating nanocarriers for the enhanced oral delivery of antibody drugs 2026-09-09

Fluorescently labeled Angiopep-2-conjugated-PAMAM nanoparticles to evaluate drug brain-targeted delivery performance 2026-09-02

Insights into the use of artificial intelligence in the drug discovery and delivery of nanosystems for the treatment of infectious diseases and neoplasms 2026-09-01

Ultrasound-responsive microencapsulated curcumin nanobubbles for treatment of mice rheumatoid arthritis and mechanistic insights based on single-cell Transcriptomics 2026-08-24

Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma 2026-08-20

Understanding <i>Mycobacterium tuberculosis</i> host immune responses and identifying synergistic autophagy-inducing compounds as potential nanomedicines for tuberculosis treatment 2026-08-25

Nanoparticles for fluorescence-guided breast cancer surgery: advances in <i>in vivo</i> preclinical research 2026-08-18